10/07/2026
Stargardt disease is the most common inherited form of juvenile macular dystrophy, primarily caused by mutations in the ABCA4 gene passed down in an autosomal recessive pattern, meaning a child must inherit a faulty copy from each parent. In a healthy eye, this gene produces a specialized protein that functions like a molecular trash collector within the retina, the light-sensitive tissue lining the back of the eye. Every time the eye detects light, it consumes vitamin A, which naturally creates chemical byproducts that must be cleared away and recycled. When the ABCA4 protein is defective, this cleaning mechanism stalls, causing toxic fatty waste called lipofuscin to build up inside the retinal support cells. Over time, this toxic accumulation starves and destroys light-detecting photoreceptors in the macula, the center of the retina responsible for sharp, detailed sight, leading to progressive central vision loss, blind spots, and difficulty reading or recognizing faces.
While there is currently no approved cure, recent clinical trials are demonstrating significant promise to slow or stabilize the condition. The most advanced front of research involves oral medications designed to halt the accumulation of toxic retinal debris at its source. A leading candidate, tinlarebant, works by selectively restricting how much vitamin A enters the eye, successfully slowing the rate of retinal damage in global Phase 3 trials. Another major oral therapy under investigation, gildeuretinol (ALK-001), supplies the body with a chemically reinforced form of vitamin A that functions normally for sight but resists clumping into toxic waste. Alongside these daily oral treatments, scientists are testing gene therapies designed to deliver healthy ABCA4 genes directly into retinal cells, as well as stem cell transplants that aim to replace damaged retinal cells, together marking one of the most hopeful eras of development for Stargardt disease.